Persistence of Immunity to Varicella in Children with Leukemia Immunized with Live Attenuated Varicella Vaccine

作者: Anne A. Gershon , Sharon P. Steinberg ,

DOI: 10.1056/NEJM198904063201403

关键词:

摘要: To determine the safety and efficacy of varicella vaccine, we studied 437 children in remission from leukemia who were immunized with live attenuated virus. Three hundred one patients received two doses vaccine 136 a single dose 1 10 lots manufacturers. The have been followed for an average three years (range, to six). Seroconversion occurred 88 percent after first 98 or doses. proportions seronegative one, three, five 20, 25, 30 percent, respectively, little change over time geometric mean titers specific antibody (6.3, 6.5, 5.7, respectively). Chickenpox has documented 36 vaccinated (8 percent) had 3 640 vesicles (mean, 100), mild illness, no complications. Of 83 exposed within their families, 11 chickenpox; attack rate was 14 among seropositive patients, 29 patients). There relation between since vaccination either severity breakthrough illness. Two appeared be more effective than dose. 372 receiving maintenance chemotherapy when immunized, 149 (40 rash, which treated acyclovir 16 (4 became severe febrile illness 4. These reactions not fatal all associated lots, use discontinued. We conclude that leukemia, is safe induces immunity chickenpox persists years.

参考文章(18)
S P Steinberg, A A Gershon, L Gelb, Live Attenuated Varicella Vaccine Use in Immunocompromised Children and Adults Pediatrics. ,vol. 78, pp. 757- 762 ,(1986)
Lisa Frierson, Jean Taylor-Wiedeman, Clementina F. Geiser, Eva Lydick, Philip A. Brunell, Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics. ,vol. 77, pp. 53- 56 ,(1986)
S Feldman, L Lott, Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. ,vol. 80, pp. 465- 472 ,(1987)
Luba K. Vujcic, Yoshizo Asano, Gerald V. Quinnan, Michiaki Takahashi, Paul Albrecht, Katsuro Kawakami, Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics. ,vol. 72, pp. 291- 294 ,(1983)
Stanley A. Plotkin, Varicella vaccine: a point of decision. Pediatrics. ,vol. 78, pp. 705- 707 ,(1986)
A. A. Gershon, S. P. Steinberg, P. LaRussa, A. Ferrara, M. Hammerschlag, L. Gelb, , Immunization of Healthy Adults with Live Attenuated Varicella Vaccine The Journal of Infectious Diseases. ,vol. 158, pp. 132- 137 ,(1988) , 10.1093/INFDIS/158.1.132
Robert E. Weibel, Beverly J. Neff, Barbara J. Kuter, Harry A. Guess, Carol A. Rothenberger, Alison J. Fitzgerald, Karen A. Connor, Arlene A. McLean, Maurice R. Hilleman, Eugene B. Buynak, Edward M. Scolnick, Live Attenuated Varicella Virus Vaccine New England Journal of Medicine. ,vol. 310, pp. 1409- 1415 ,(1984) , 10.1056/NEJM198405313102201
Michiaki Takahashi, Terumasa Otsuka, Yoshiomi Okuno, Yoshizo Asano, Takehiko Yazaki, Shin Isomura, LIVE VACCINE USED TO PREVENT THE SPREAD OF VARICELLA IN CHILDREN IN HOSPITAL The Lancet. ,vol. 304, pp. 1288- 1290 ,(1974) , 10.1016/S0140-6736(74)90144-5
Stephen R. Preblud, Varicella: Complications and Costs Pediatrics. ,vol. 78, pp. 728- 735 ,(1986)
Charles Marwick, Varicella Vaccine Licensing in 18 to 24 Months? JAMA: The Journal of the American Medical Association. ,vol. 258, pp. 3215- 3216 ,(1987) , 10.1001/JAMA.1987.03400220013003